Key facts
- Ambrosia Biosciences’s last known valuation is $203.0M (Mar 2026).
- It has raised $125.0M across 1 recorded rounds; the latest was Early Stage VC ($16.0M) in Jul 2024.
- Notable investors include Blue Owl Capital, Samsara BioCapital, Redmile Group, Deep Track Capital, BVF Partners — 8 tracked in total.
- Ambrosia Biosciences has filed 2 Form Ds with the SEC, most recently Aug 2024 ($16.0M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Ambrosia Biosciences
Funding rounds
1 roundsAbout Ambrosia Biosciences
Operator of a metabolic disease biotech company intended to treat obesity and other metabolic disorders. The company offers non-invasive methods and small molecule-based therapies for weight management and metabolic health, enabling patients to manage conditions effectively with fewer side effects compared to other traditional medications.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2024
- Employees
- 35
- Website
- ambrosiabiosciences.com/
- Ownership
- Privately Held (backing)
Ambrosia Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ambrosia Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ambrosia Biosciences in its N-PORT filings yet. We sweep new filings monthly.